These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37442373)

  • 21. Piperacillin/tazobactam-resistant, cephalosporin-susceptible
    Edwards T; Heinz E; van Aartsen J; Howard A; Roberts P; Corless C; Fraser AJ; Williams CT; Bulgasim I; Cuevas LE; Parry CM; Roberts AP; Adams ER; Mason J; Hubbard ATM
    Microb Genom; 2022 Apr; 8(4):. PubMed ID: 35404783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Confronting Ceftolozane-Tazobactam Susceptibility in Multidrug-Resistant Enterobacterales Isolates and Whole-Genome Sequencing Results (STEP Study).
    Hernández-García M; García-Fernández S; García-Castillo M; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Costa E; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva T; Chaves C; Pássaro L; Paixão L; Romano J; Cantón R;
    Int J Antimicrob Agents; 2021 Feb; 57(2):106259. PubMed ID: 33310115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Evaluation of susceptibility and response to therapy with piperacillin-tazobactam in patients with infections caused by Escherichia coli with extended-spectrum β-lactamase (ESBL) CTX-M].
    Álvarez J; Rojas Á; Carvajal C; Revello J; Meza P; Guggiana P; García P; Labarca J
    Rev Chilena Infectol; 2018 Aug; 35(4):343-350. PubMed ID: 30534919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
    Bethel CR; Hujer AM; Helfand MS; Bonomo RA
    FEMS Microbiol Lett; 2004 May; 234(1):99-103. PubMed ID: 15109726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial Resistance Pattern and Genetic Characteristics of ESBL and Carbapenemase-producing Escherichia coli at a Tertiary Care Hospital in Bangladesh.
    Khan ER; Paul SK; Kobayashi N; Khan TR; Rahman MH; Rahman MM
    Mymensingh Med J; 2020 Jan; 29(1):37-42. PubMed ID: 31915333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Point mutations in the inc antisense RNA gene are associated with increased plasmid copy number, expression of blaCMY-2 and resistance to piperacillin/tazobactam in Escherichia coli.
    Kurpiel PM; Hanson ND
    J Antimicrob Chemother; 2012 Feb; 67(2):339-45. PubMed ID: 22117029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
    Prabhu V; Foo J; Ahir H; Sarpong E; Merchant S
    J Med Econ; 2017 Aug; 20(8):840-849. PubMed ID: 28532194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
    Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
    J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
    Popejoy MW; Paterson DL; Cloutier D; Huntington JA; Miller B; Bliss CA; Steenbergen JN; Hershberger E; Umeh O; Kaye KS
    J Antimicrob Chemother; 2017 Jan; 72(1):268-272. PubMed ID: 27707990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
    Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL;
    JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Whole genome sequence of an MCR-1-carrying, extended-spectrum β-lactamase (ESBL)-producing Escherichia coli ST746 isolate recovered from a community-acquired urinary tract infection.
    Wu L; Chen J; Wang L; Wu Z
    J Glob Antimicrob Resist; 2018 Jun; 13():171-173. PubMed ID: 29626525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial Susceptibilities of Aerobic and Facultative Gram-Negative Bacilli from Intra-abdominal Infections in Patients from Seven Regions in China in 2012 and 2013.
    Zhang H; Yang Q; Liao K; Ni Y; Yu Y; Hu B; Sun Z; Huang W; Wang Y; Wu A; Feng X; Luo Y; Hu Z; Chu Y; Chen S; Cao B; Su J; Gui B; Duan Q; Zhang S; Shao H; Kong H; Badal RE; Xu Y
    Antimicrob Agents Chemother; 2016 Jan; 60(1):245-51. PubMed ID: 26482308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors determining resistance to beta-lactam combined with beta-lactamase inhibitors in Escherichia coli.
    Reguera JA; Baquero F; Pérez-Díaz JC; Martínez JL
    J Antimicrob Chemother; 1991 May; 27(5):569-75. PubMed ID: 1653204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane.
    Vanscoy B; Mendes RE; McCauley J; Bhavnani SM; Bulik CC; Okusanya OO; Forrest A; Jones RN; Friedrich LV; Steenbergen JN; Ambrose PG
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5924-30. PubMed ID: 24041895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors for infection or colonization with CTX-M extended-spectrum-β-lactamase-positive Escherichia coli.
    Han JH; Kasahara K; Edelstein PH; Bilker WB; Lautenbach E
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5575-80. PubMed ID: 22890772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
    Bulik CC; Tessier PR; Keel RA; Sutherland CA; Nicolau DP
    Antimicrob Agents Chemother; 2012 Jan; 56(1):544-9. PubMed ID: 22064538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and types of extended spectrum β-lactamases among urinary Escherichia coli isolates in Moroccan community.
    Barguigua A; El Otmani F; Talmi M; Zerouali K; Timinouni M
    Microb Pathog; 2013; 61-62():16-22. PubMed ID: 23643553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of ceftolozane-tazobactam against Escherichia coli isolates from U.S. veterans (2011) in relation to co-resistance and sequence type 131 (ST131) H30 and H30Rx status.
    Johnston BD; Thuras P; Johnson JR
    PLoS One; 2018; 13(7):e0200442. PubMed ID: 29990385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imipenem-Relebactam Susceptibility in
    Hernández-García M; García-Castillo M; Bou G; Cercenado E; Delgado-Valverde M; Oliver A; Pitart C; Rodríguez-Lozano J; Tormo N; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Cruz H; Chaves C; Duarte J; Pássaro L; Díaz-Regañón J; Cantón R
    Microbiol Spectr; 2022 Oct; 10(5):e0292722. PubMed ID: 36043877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.